Starpharma (ASX: SPL, OTCQX: SPHRY), which is dedicated to enhancing the quality of life for patients with unmet medical needs, such as cancer, by creating innovative therapies using dendrimer technology, today releases its Quarterly Activities Report and Appendix 4C for the period ended 31 March 2024 (Q3 FY24). Starpharma’s closing cash balance as at 31 March 2024 was $26.6 million.

"SPL has developed its proprietary Dendrimer Enhanced Products platform (DEP) to improve the effectiveness and safety of drugs, especially cancer treatments." Read the full article in Stockhead. 

DEP is based on dendrimers, which are highly branched polymers, to enhance the delivery of cancer treatments and reduce toxic side effects such as neutropenia, nausea, severe diarrhoea and hair loss from chemotherapy agents. Read the full article in The Australian Business Review. 

Cheryl Maley, CEO of Starpharma (SPL), provides insight into the partnreship with Medicxi, materialising in Petalion Therapeutics in the UK. 

"Australian biotech Starpharma Holdings (ASX: SPL) has entered into a strategic partnership with UK life sciences investment firm Medicxi to establish a UK-based company known as Petalion Therapeutics." 

Medicxi to invest up to USD $25M into newly established entity, Petalion Therapeutics, led by highly experienced pharmaceutical executive Dr Mehdi Shahidi

Starpharma (ASX: SPL, OTCQX: SPHRY) is pleased to announce that it will host an investor webinar on Tuesday, 9 April 2024.

Starpharma (ASX: SPL, OTCQX: SPHRY) today releases its Interim Report and Half-Year Financial Results for the period ended 31 December 2023 (H1 FY24).